Chronic Obstructive Pulmonary Disease | Treatment Algorithms: Claims Data Analysis | US | 2023

Long-acting beta2 agonist (LABA) / long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) have been gaining traction in the chronic obstructive pulmonary disease (COPD) therapy market, threatening the positions of both LAMAs and LABA / inhaled corticosteroid (ICS) FDCs. Because of the progressive and irreversible nature of COPD, many patients eventually require more-aggressive treatment and are prescribed a combination of a LABA, a LAMA, and an ICS, providing a market opportunity for the triple-therapy combinations (e.g., Trelegy, Breztri). The launch and uptake of generic versions of blockbuster inhaled drugs (e.g., salmeterol / fluticasone, formoterol / budesonide, and albuterol sulfate) increase the affordability of treatment, further changing prescribing patterns.

Questions answered

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed COPD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed COPD patients?
• How have Breztri and Trelegy been integrated into the treatment algorithm, and what are their sources of business?
• What percentage of COPD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of COPD patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Solution enhancement

The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.

Geography: United States

Real world data: Longitudinal patient-level claims data analysis

Key drugs covered: ProAir HFA, albuterol sulfate HFA, Advair, AirDuo, Breo, Dulera, Symbicort, Wixela, Incruse, Lonhala, Spiriva, Yupelri, Anoro, Bevespi, Stiolto, Combivent, Pulmicort, Brovana, Daliresp, Trelegy, Breztri

Key analysis provided: Brand / therapy usage across longitudinal patient sample; newly diagnosed patient analysis; treatment initiation and progression; line of therapy analysis; combination therapy analysis; source of business for recently treated patients; persistency and compliance analysis; product-level patient flowcharts